<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza A and B viruses are important human respiratory pathogens that cause annual epidemics worldwide. Anti-influenza prophylaxis and treatment with antiviral drugs are used to prevent and control influenza virus infections, particularly when vaccines are ineffective or unavailable [
 <xref rid="pone.0190877.ref001" ref-type="bibr">1</xref>]. The Centers for Diseases Control and Prevention (CDC) has reported high levels of resistance (&gt;99%) to adamantanes among circulating seasonal influenza A(H3N2) and pandemic A(H1N1)pdm09 viruses [
 <xref rid="pone.0190877.ref002" ref-type="bibr">2</xref>]. Therefore, existing options for the prophylaxis and treatment of influenza virus infection are limited to a single class of antiviral drug, neuraminidase inhibitors (NAIs). Three NAIs, namely oral oseltamivir, inhaled zanamivir, and intravenous peramivir, are approved by the United States Food and Drug Administration and are recommended for the prophylaxis and treatment of patients infected with influenza A or B viruses [
 <xref rid="pone.0190877.ref002" ref-type="bibr">2</xref>].
</p>
